

ACKNOWLEDGMENTS

Most of the original data for the USRDS are provided by the Health Care Financing Administration through the Interagency Agreement between the NIDDK/DKUHD of the National Institutes of Health, and the Bureau of Data Management and Strategy of the Health Care Financing Administration.

The U.S. Renal Data System offers its most grateful appreciation to everyone who helped to make this **USRDS 1994 Annual Data Report** a reality, especially all the ESRD professionals and Networks on whose reporting of data this enterprise ultimately rests.

Lawrence Y.C. Agodoa, M.D.
USRDS Project Officer
NIH/NIDDK/DKUHD

Philip J. Held, Ph.D.
Director, USRDS Coordinating Center
The University of Michigan

Friedrich K. Port, M.D., M.S.
Deputy Director, USRDS Coordinating Center
The University of Michigan

SUGGESTED CITATION

The suggested citation for this report is as follows:

U.S. Renal Data System, **USRDS 1994 Annual Data Report**,
The National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases,
Bethesda, MD, June 1994.

Publications based upon USRDS data reported here or supplied upon request must include the citation as noted above and the following notice:

The data reported here have been supplied by The United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.

The USRDS would like to thank the members of the Biomedical and Economic Scientific Advisory Committees who generously donated their time to a peer review of this 1994 Annual Data Report.

The USRDS 1994 Annual Data Report

Table of Contents

	Page
List of Common Acronyms.....	ix
Executive Summary	xiii
 CHAPTERS	
I. The USRDS	1
II. Access to the USRDS Data.....	7
III. Prevalence and Cost of ESRD Therapy.....	23
IV. Incidence and Causes of Treated ESRD	43
V. ESRD Treatment Modalities.....	55
VI. Patient Survival	79
VII. Causes of Death	95
VIII. Renal Transplantation: Access and Outcomes	107
IX. Pediatric End Stage Renal Disease	129
X. Cost Effectiveness As Applied to ESRD.....	151
XI. Facility Survey of Providers of ESRD Therapy	163
XII. International Comparisons of ESRD Therapy.....	171
XIII. USRDS Research Studies.....	179
XIV. A Guide to the USRDS Database	187
XV. Analytical Methods.....	207
 REFERENCE TABLES	
Table of Contents and Introduction	
A. Incidence of Reported ESRD Therapy	
B. Prevalence of Reported ESRD Therapy	
C. Methods of Treatment	

- D. Mortality and Causes of Death**
- E. Patient Survival**
- F. The Kidney Transplant Process**
- G. Transplant Outcome**
- H. Hospitalization**
- I. Institutional Providers**
- J. Census Population Base**

APPENDICES

A. USRDS Papers, Abstracts and Presentations

B. Selected Special Studies Data Collection Forms

Case Mix Adequacy Study

(Patient and Dialysis Forms)

1992 Administration to 1992 Prevalent Patients

Case Mix Severity Study

1989 Administration to 1986-87 Incident Patients

CAPD Peritonitis Study

1989-90 Administration to Patients trained for CAPD January - June 1989

Pediatric Growth and Development Study

1991 Administration to Patients born after December 31, 1970 and treated in at least one dialysis or transplant unit for 30 consecutive days or more during 1990